Aurobindo Pharma Acquires A1 Labs LLC For ₹127.32 Crore

On October 2, 2026, Aurobindo Pharma announced the acquisition of A1 Biochem Labs LLC, a company specializing in contract research and chemistry services for pharmaceutical and biotechnology firms. The deal, valued at USD 15.247 million, amounted to roughly ₹127.32 crore. Located in Wilmington, North Carolina, A1 Labs LLC provided services like custom synthesis and medicinal chemistry to clients in the pharmaceutical industry.

Following the acquisition, A1 Labs LLC would transition into a step-down subsidiary of A1 Labs India, with Apitoria now owning an 80% stake in the entity.

Aurobindo Pharma's acquisition of A1 Labs LLC aimed to bolster its presence in the Active Pharmaceutical Ingredients (API) sector. The pharmaceutical giant expects to establish a dedicated Contract Research, Development, and Manufacturing (CRDMO) platform through this strategic move. The company reported total sales of USD 9.23 million for the fiscal year ending December 31, 2024, and USD 5.92 million for the fiscal year ending December 31, 2025.

This acquisition is categorized as a related party transaction, involving A1 Labs LLC's sale to Rajendra Gadikota, who also holds a director position at A1 Labs India. The deal, not subject to any governmental or regulatory approvals, was finalized without the need for such clearances. Aurobindo Pharma's expansion into the US dermatology market is further facilitated by the launch of ADQUEY Ointment for atopic dermatitis.